Targeting Cellular Senescence in Renal Aging: Therapeutic Opportunities and Challenges

Abstract

Cellular senescence is increasingly recognized as a critical driver of kidney aging and chronic kidney disease (CKD). Senolytic therapies, which selectively eliminate senescent cells, have emerged as a promising strategy to mitigate age-related renal dysfunction. This review synthesizes current evidence on the role of senescent cells in kidney aging, elucidates mechanisms of action of senolytics, examines epidemiological and clinical data, and discusses the potential integration of these agents into nephrology practice. We provide an academic perspective for clinicians and researchers, emphasizing translational relevance, emerging therapies, and guideline considerations.

Introduction

The aging kidney is characterized by structural and functional decline, predisposing individuals to CKD, acute kidney injury, and related comorbidities. Recent advances in geroscience spotlight cellular senescence a state of irreversible cell cycle arrest accompanied by a pro-inflammatory secretory phenotype as a key contributor to renal aging. Senolytic agents, which induce selective apoptosis of senescent cells, represent a novel class of therapeutics with the potential to arrest or reverse aging phenotypes in the kidney. This article reviews the current landscape of senolytics in kidney aging, with a focus on mechanism-based insights and clinical translation.

Epidemiology / Disease Burden

Globally, the burden of CKD and age-related renal dysfunction is rising in tandem with increased life expectancy. Epidemiological data indicate that more than 10% of the global population is affected by CKD, with prevalence sharply increasing among individuals over 65 years. Aging is associated with a decline in glomerular filtration rate (GFR), nephron loss, and increased susceptibility to nephrotoxic insults. The cumulative effects of cellular damage and impaired regenerative capacity underpin the high morbidity and healthcare costs associated with kidney aging. Importantly, cellular senescence has been implicated as a unifying process linking aging to CKD progression in diverse populations.

Pathophysiology

Senescent cells accumulate in the kidney with age and in response to stressors such as hypertension, diabetes, and ischemic injury. These cells exhibit altered gene expression, resistance to apoptosis, and secretion of pro-inflammatory cytokines, chemokines, and matrix metalloproteinases the so-called senescence-associated secretory phenotype (SASP). SASP disrupts the renal microenvironment, promotes fibrosis, impairs tubular regeneration, and perpetuates inflammation, collectively accelerating renal aging and CKD progression. The p16INK4a and p21CIP1/WAF1 pathways are central to the induction and maintenance of the senescent phenotype in renal cells.

Risk Factors

Risk factors for accelerated kidney aging and senescence include advanced chronological age, metabolic syndrome, diabetes mellitus, hypertension, chronic exposure to nephrotoxins, and genetic predisposition. Oxidative stress, telomere attrition, and DNA damage are common triggers of cellular senescence in the kidney. Additional contributors such as chronic inflammation, mitochondrial dysfunction, and impaired autophagy further promote the accrual of senescent cells in renal tissues.

Clinical Features

Clinically, kidney aging manifests as progressive decline in GFR, impaired urine concentrating ability, increased albuminuria, and hypertension. Elderly patients may also exhibit greater susceptibility to acute kidney injury, electrolyte disturbances, and slower recovery from nephrotoxic insults. Biomarkers of cellular senescence such as increased expression of p16INK4a, senescence-associated β-galactosidase activity, and elevated SASP factors have been detected in renal biopsies from aged individuals and those with CKD, correlating with disease severity.

Diagnosis

The diagnosis of kidney aging relies on clinical, laboratory, and histopathological parameters. Declining GFR, rising serum creatinine, and increased urinary albumin excretion are standard laboratory markers. Renal biopsy may reveal glomerulosclerosis, interstitial fibrosis, tubular atrophy, and accumulation of senescent cells as evidenced by immunohistochemical staining for p16INK4a and β-galactosidase. Recent advances in molecular diagnostics have enabled the detection of circulating SASP components and microRNAs as non-invasive biomarkers of renal senescence, potentially facilitating earlier identification and risk stratification.

Treatment & Management

Traditional management of kidney aging focuses on risk factor modification, blood pressure control, glycemic management, and avoidance of nephrotoxins. Renoprotective agents such as ACE inhibitors, ARBs, and SGLT2 inhibitors have demonstrated efficacy in slowing CKD progression. However, none of these interventions directly target the underlying process of cellular senescence. Supportive measures, including optimization of fluid status, correction of metabolic derangements, and management of comorbidities, remain cornerstones of care for elderly patients with renal impairment.

Recent Advances / Emerging Therapies

Senolytic agents including dasatinib, quercetin, navitoclax, and fisetin have demonstrated the ability to selectively eliminate senescent cells in preclinical models of renal aging. These agents act via distinct mechanisms: dasatinib inhibits tyrosine kinases, quercetin modulates anti-apoptotic pathways, and navitoclax targets BCL-2 family proteins. Animal studies reveal that senolytic treatment reduces renal SASP burden, improves GFR, attenuates fibrosis, and restores regenerative potential. Early-phase human trials are underway, with preliminary evidence suggesting safety, tolerability, and reduction in senescence biomarkers. Challenges remain, including optimizing dosing regimens, minimizing off-target effects, and identifying patients most likely to benefit.

Guideline Recommendations

Current clinical guidelines do not yet incorporate senolytic therapies for kidney aging, as robust phase III trial data are lacking. However, expert consensus emphasizes the importance of recognizing cellular senescence as a therapeutic target and encourages participation in clinical trials evaluating senolytics. Future guideline updates may include recommendations based on accumulating evidence for efficacy, safety, and patient selection criteria. For now, clinicians should focus on established renoprotective strategies while remaining informed about ongoing advances in senescence-targeted therapies.

Conclusion

The accumulation of senescent cells represents a fundamental mechanism driving kidney aging and CKD progression. Senolytic therapies offer a novel avenue to ameliorate age-related renal dysfunction by selectively eliminating these pathogenic cells. While preclinical data and early clinical studies are promising, further research is required to establish the long-term efficacy and safety of senolytics in human populations. Integration of senescence-targeted therapies into nephrology practice has the potential to transform outcomes for elderly patients, underscoring the need for continued scientific and clinical investigation in this rapidly evolving field.